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Abstract Tumor treating ﬁelds (TTFields) are low
intensity, intermediate frequency, alternating electric ﬁelds
used to treat cancerous tumors. This novel treatment
modality effectively inhibits the growth of solid tumors in
vivo and has shown promise in pilot clinical trials in
patients with advanced stage solid tumors. TTFields were
tested for their potential to inhibit metastatic spread of
solid tumors to the lungs in two animal models: (1) Mice
injected with malignant melanoma cells (B16F10) into the
tail vein, (2) New Zealand White rabbits implanted with
VX-2 tumors within the kidney capsule. Mice and rabbits
were treated using two-directional TTFields at 100–
200 kHz. Animals were either monitored for survival, or
sacriﬁced for pathological and histological analysis of the
lungs. The total number of lung surface metastases and the
absolute weight of the lungs were both signiﬁcantly lower
in TTFields treated mice then in sham control mice.
TTFields treated rabbits survived longer than sham control
animals. This extension in survival was found to be due to
an inhibition of metastatic spread, seeding or growth in the
lungs of TTFields treated rabbits compared to controls.
Histologically, extensive peri- and intra-tumoral immune
cell inﬁltration was seen in TTFields treated rabbits only.
These results raise the possibility that in addition to their
proven inhibitory effect on the growth of solid tumors,
TTFields may also have clinical beneﬁt in the prevention of
metastatic spread from primary tumors.
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Introduction
Pulmonary metastases, a common outcome of primary
cancerous tumors, are present in 20–54% of all patients
who die of cancer and are very often the cause of death of
the patient [1, 2]. The survival rate for patients with pul-
monary metastases is dependent upon the location of the
primary tumor, its histology and differentiation, number of
lesions, the presence of mediastinal nodal disease and the
resectability of the tumor [2–5]. The 3 years survival rate
from diagnosis of pulmonary metastases is about 0% for
patients with hepatocellular carcinoma [6] and the 3-year
survival rate from diagnosis is 25% for patients with soft
tissue sarcoma [3].
Examples of the prevalence of metastases include: epi-
thelial (43%), sarcoma (42%), germ cell (7%) and mela-
noma (6%) [4]. The extrathoracic tumors that frequently
metastasize to the lungs are: stomach, uterus, breast,
colorectal, head-and-neck, and renal [2, 7, 8].
Current treatments for pulmonary metastases include the
following: metastasectomy, which is often the patient’s
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less than 50% in most cases [2]; chemotherapy and
radiotherapy that are usually given as an adjunct to surgery
with some beneﬁcial effect but also hold a potential risk
due to signiﬁcant side effects [9]; hormonal therapy with a
relatively low response rate [10]; thermal ablation which
has shown promising results in preliminary experiments [9,
11, 12] but holds the risk of excessive heat of the sur-
rounding tissue; and ﬁnally, immuno-chemotherapy which
has shown signiﬁcant therapeutic efﬁcacy, however, only
in speciﬁc tumor types [13].
Despite all the progress made in past years, the clinical
outcome of the above mentioned treatments is still poor.
This could be attributed in part to tumor avoidance of
immuno-editing [14]. The identiﬁcation of tumor-associ-
ated antigens as ‘self’, leads to only a partial immune
response and is one of the factors that limits the ability of
the body to achieve recovery [15]. Furthermore, chemo-
therapy as well as stress induced by surgery are also factors
that attenuate the immune system and weaken the immune
response, thus further reducing the ability of the body to
recover from these insults [16, 17].
Recently, a novel anti-cancer treatment modality, named
Tumor Treating Fields (TTFields) was introduced.
TTFields are low intensity, intermediate frequency alter-
nating electric ﬁelds that were shown to disrupt cancer cell
replication in vitro and to slow tumor progression in animal
cancer models and patients with recurrent and newly
diagnosed glioblastoma [18–20]. Yet, little is know about
the effect of TTFields on the metastatic spread of solid
tumors. The application of TTFields to animals and
patients has been shown to have almost no acute or chronic
toxicity [18, 20]. Speciﬁcally, due to the relatively high
frequency of TTFields ([100 kHz), these ﬁelds do not
stimulate nerves or muscles and thus have no effect on
cardiac pacing. In addition, the low intensity used (single
volts per cm), does not cause signiﬁcant heating within the
body [18, 20]. The purpose of the present work is to test the
effect of TTFields on metastasis formation in two animal
models and to investigate the development of an immune
response following TTFields treatment.
Materials and methods
TTFields were tested for their potential to inhibit metastatic
spread of solid tumors to the lungs in two animal models:
malignant melanoma in mice and VX-2 tumors in rabbits.
Animal experiments were conducted in accordance with
the Technion—Israel Institute of Technology guidelines
for the care of laboratory animals.
TTFields generating system as well as the electric ﬁelds
measurement device were described elsewhere [18, 19].
The electric ﬁelds intensities are expressed in Volts (peak
to peak) per cm.
TTFields treatment of a melanoma lung metastases
model in mice
Female C57BL/6 mice (n = 35), weighing 20 ± 0.3 g,
were inoculated IV with a mouse malignant melanoma cell
line (B16F10). Immediately following inoculation the mice
were separated randomly into the two treatment groups.
TTFields treatment was applied through four insulated
electrodes placed around the mouse’s torso (Fig. 1a).
TTFields were applied in two perpendicular directions to
the entire mouse torso with a duty cycle of 1:1 s. The
TTFields frequency was set at 100 kHz, with currents of
90–100 mA which corresponds to electric ﬁeld intensities
of 1.8–2 V/cm within the mouse abdomen and lungs.
Control mice were treated by means of sham electrodes
which were both temperature, and geometrically matched to
the TTFields group. Treatment was applied for 7 days
continuously and the mice were sacriﬁced for lung evalu-
ation either 1 or 7 days after treatment termination. Meta-
static load in the lungs was assessed by weighing the lungs
and by counting the number of lesions seen on the external
surface of the lungs (after replacing the blood with saline to
improve visibility).
Fig. 1 Placement of electrodes on mice (a) and rabbits (b). The four
insulated electrodes were attached to the skin using hydrogel after
depilation. The electrodes were wrapped with leucoplast and
electrodes wires were connected to the TTFields generating system
or to the sham control system. The four electrodes were functionally
divided into two pairs each generating one ﬁeld direction through the
animal. The electrode pairs were placed so as to create two
perpendicular ﬁeld directions at the center of body. Sham electrodes
were placed in the same conﬁguration
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of pulmonary metastases, and the local immune
response in rabbits
Adult New Zealand White Rabbits weighting 2.5–3 kg
were implanted with two fragments of VX-2 tumors of
about 1 9 1 mm each under the left kidney capsule of each
rabbit under anesthesia. Two weeks after tumor implanta-
tion, baseline MRI was performed to detect the presence of
tumor and to assess its baseline volume.
On the day following the baseline MRI, 4 electrode
arrays each consisting of 9 insulated electrodes (2.85 mm
2
each) connected in parallel were placed on torso of each
tumor bearing animal of the treated group. The electrode
arrays were placed on the abdomen, back and both ﬂanks of
the animal at the level of the kidneys (Fig. 1b). Identically
shaped sham electrodes were placed on torso of each ani-
mal from the control group. Each sham electrode array was
provided with an electrical heating element to match the
temperature generated on the skin by the TTFields treat-
ment electrodes. Both the treatment and the sham treatment
electrodes included temperature sensors to monitor the
temperature at the skin-electrode interface.
The animals in the treatment group were exposed to
TTFields and those in the control group to heating. Six
rabbits (in each experiment), were treated with TTFields
for 5 weeks continuously. TTFields parameters were
monitored and adjusted manually 1–3 times daily.
The rabbits were treated to the abdomen and retroperi-
toneum (but not lungs) using two directional 200 kHz
TTFields with average current of 790 ± 80 mA (which
correspond to 2.6 ± 0.3 V/cm in the kidney) and duty
cycle of 1 s. After each week of treatment electrodes were
removed and all animals underwent T1 weighted MRI of
the left kidney using a GI Genesis-Signa MRI device (at
the Rambam Medical Center, Haifa, Israel). After the MRI
the electrodes were replaced and treatment continued for a
total treatment period of 35 days. Tumor volume assess-
ment by MRI was performed by a technician blinded to the
group of each rabbit.
Following treatment, animals were either followed for
survival, or sacriﬁced for pathological and histological
analysis of the primary kidney tumor and lung metastases.
Data analysis
Average tumor volumes in treated rabbits were compared
to the average tumor volumes in the sham rabbits in each
experiment. Statistical analysis of tumor growth rates,
with reference to baseline was performed using the student
t-test. The number of metastases and their size distribution
were compared between groups using the Chi-squared
test.
The survival time was taken as number of days from the
implantation to the day the animal died. For both treated
and control groups the median survival time was calcu-
lated. The statistical signiﬁcance between the survival
curves was analyzed using the Log-Rank test.
The subsequent parameters were inspected using micro-
scopic investigation: tumor diameter, number of nodules
per section and the extent of necrosis and inﬁltration by
mononuclear cells. Histological slides from the lungs of
TTFields treated and control rabbits were stained for
immunological markers to demonstrate different popula-
tions of immune cells in the tissue. The extent of the intra-
tumoral inﬁltration of the lymphocyte subsets was assessed
by semi-quantitative score with increasing severity (0–5).
Results
TTFields treatment of a melanoma lung metastases
model in mice
Continuous TTFields treatment for 7 days reduced the size
and number of lung melanoma metastases at the end of
treatment as compared to sham controls. Representative
photos of lungs from treated and control mice are shown in
Fig. 2a and b, respectively. The average number of surface
metastases per lung in the TTFields group was signiﬁcantly
lower than in sham controls: 1.5 ± 1 compared to
10.3 ± 8.4, respectively (Fig. 2c; P\0.01). The average
lung weight of the TTFields treated animals was also sig-
niﬁcantly lower than the average lung weight in the control
group (212 ± 10 vs. 253 ± 20 mg, respectively; P\0.01;
see Fig. 2d).
When mice were followed for an additional week after
termination of the TTField treatment, the overall number of
lung metastases was similar in TTFields and sham control
animals (18 ± 12 vs. 17 ± 15, respectively; P = 0.87) and
the lung weights were practically identical (370 ± 28 vs.
365 ± 40 mg, respectively; P = 0.79). However, the dis-
tribution of metastasis sizes differed signiﬁcantly between
the groups (P\0.05, Chi-squared test) with a higher
proportion of large metastases seen in the control group,
and a higher proportion of small metastases in the TTFields
treated group (Fig. 3).
Effect of TTFields therapy on the formation and growth
of pulmonary metastases, and the local immune
response in rabbits
Primary tumor
The baseline average tumor volume in the sham control
rabbits and in treated rabbits was identical (1.19 ± 1.1 vs.
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3, respectively; P = 0.97). The average
tumor volume after treatment was half of the volume of
untreated sham controls (29.0 ± 18.5 vs. 61.1 ± 38.5 cm
3,
respectively; P = 0.0011). The average daily growth rate
of the TTFields treated tumors was also signiﬁcantly lower
than that of the sham controls (1.2 ± 1.1 vs. 3.5 ± 3.2,
respectively; P = 0.003). Figure 4 shows examples of T1
weighted MRI images (with gadolinium) of the maximal
cross-sectional area of the tumor in representative treated
versus sham control rabbits. The tumor in both images is
hypo-intense with a ring-like contrast enhancement and
necrotic center. The maximal tumor cross-section in the
treated animal (Fig. 4a) is about half of that seen in the
control animal (Fig. 4b).
Animal survival
The median survival of TTFields treated animals was
70 days which is signiﬁcantly longer than the 57 days of
the control animals (Log-Rank test; P\0.05). The Kap-
lan–Meier survival curve of the treatment results is shown
in Fig. 5. This ﬁnding was surprising since the damage to
the kidneys was unilateral in all animals. This fact together
with the appearance of respiratory failure in most animals
prior to their demise, led us to investigate the possibility of
a difference in the metastatic load in TTFields treated
versus sham control rabbits.
Lung metastases
The average TTFields intensities in the lung were 0.5 V/cm
which is a ﬁfth of the ﬁeld intensity measured in the kidney
(see ‘‘Methods’’). Despite the fact that the ﬁeld intensity in
the lungs was too low to have an inhibitory effect on
tumors [19], when treatment was initiated before day 14
from implantation (n = 12), a signiﬁcantly lower number
of lung metastases was seen in TTFields treated rabbits
than in sham controls (Fig. 6c; P[0.05). A trend towards
a lower number of large metastases ([3 mm in diameter)
was also seen in TTFields treated group, however, here the
difference did not reach signiﬁcance (Fig. 6d; P = 0.11).
Fig. 3 Metastases number and size distribution in mice treated with
TTFields (open bars) and sham control (closed bars). The mice were
treated for 7 days followed by 7 days of recovery
Fig. 2 Malignant melanoma
metastases as seen on the
surface of the lungs of mice
treated with TTFields.
Exemplary photos of lungs of
mice treated with TTFields (a)
or sham control (b) are shown
after removal of the pulmonary
blood by perfusion with saline.
Average number of surface
metastases (±SD) in treated and
control mice (c). Average lung
weight (±SD) of treated and
control mice
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implantation, no difference was seen in the number lung
metastases between the groups.
Similar results were obtained by microscopic scanning
of histological slides of lungs in TTFields treated versus
sham control rabbits. The mean number of lung metastases
per tumor cross-section was 11.8 in TTFields treated mice
and 23.2 for the control group. Mean metastasis diameter
was 1.4 mm per tumor cross-section in TTFields treated
groups and 6.2 mm in the control group.
In the lung sections, it was noted in all preparations that
a mononuclear cell inﬁltration was present around and
within the metastases. The extent of this cell inﬁltration
was more profound in TTFields treated rabbits compared to
the controls with a mean score of 2.0 for the treatment
group and 1.4 for the control group.
In order to better appreciate the local immune reaction
within the region of the lung metastases, immuno-histo-
chemical staining for lymphocyte subsets was performed.
This investigation revealed that TTFields treated rabbits
had signiﬁcantly increased CD4, CD8, and CD45 T-cell
counts (Table 1) as compared to control.
Interestingly, though most of the immune inﬁltration
was seen in the peri-tumoral location, the most signiﬁcant
difference was the presence of an abundant intra-tumoral
inﬁltration in TTFields treated rabbits. Representative
immuno-histochemical staining of CD45 positive T-cells is
shown in Fig. 7. Among the intra-tumoral inﬁltrating cells,
CD4 T-cells were more prevalent than CD8 T-cells.
Discussion
Lung metastases are a common severe outcome of many
primary tumors. Combined treatment consisting of pul-
monary metastasectomy and chemotherapy is often the
patient’s best hope for cure, yet in most cases the 5 years
survival rate is less than 50% [2]. Thus, prevention of
metastatic spread from primary tumors is of paramount
importance.
Recently, a new treatment modality against cancerous
cells was introduced—low intensity, intermediate fre-
quency alternating electric ﬁelds or TTFields. These ﬁnely
tuned electric ﬁelds are applied using a portable battery
operated device (NovoTTF; NovoCure Ltd., Haifa, Israel)
through insulated surface electrodes, and have been shown
to inhibit the growth of primary solid tumors in both pre-
clinical and clinical studies [18, 20].
Fig. 5 Kaplan–Meier survival curve of rabbits treated with TTFields
(n = 23; red line) versus sham controls (n = 20; black line). The
median survivals of 70 vs. 57 days, respectively, are indicated by
dotted lines
Fig. 4 T1 weighted MRI
images (post gadolinium) of the
maximal cross-sectional area of
a TTFields treated (a) versus
sham control tumor (b) in rabbit
kidneys. Arrows indicate tumor
location. Scale bar 1c m
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In a preliminary attempt to study the effect of TTFields on
metastatic lesions we tested the ﬁelds’ effect when applied
directly to the lung shortly after B16F10 melanoma cells
were injected into the tail vein. After 7 days of TTFields
application, the number of surface lung metastases in the
TTFields treated mice was signiﬁcantly reduced, compared
to the sham control group. This result could be interpreted
in several ways: the TTFields could have eliminated the
B16F10 melanoma cells shortly after injection, or merely
prevented their implantation in the lung. Alternatively, the
implantation of the B16F10 melanoma cells in the lungs
was not affected but the tumor progression was inhibited
by the TTFields. The latter option is supported by the fact
that 1 week after stopping treatment the number of lung
metastases in the TTFields group was equal to the number
observed in the sham control group. Furthermore, the dif-
ferent size distribution between the two groups suggests that
the metastases progression was inhibited in the TTFields
group during treatment, an effect which may have been
attenuated or partially lost after 1 week recovery.
Inhibition of VX-2 carcinoma in rabbits’ kidneys
Previously we reported that TTFields treatment signiﬁ-
cantly reduced progression of malignant melanoma and
adenocarcinoma tumors in mice as well as glioma cells
inoculated intracranially in Fischer rats [18, 19]. In the
present study we demonstrate that TTFields can inhibit the
growth of VX-2 carcinoma in the kidneys of New Zealand
white rabbits. The MRI results illustrate that TTFields
application signiﬁcantly reduced tumor growth rate
throughout treatment.
Though the inhibition of renal tumor growth was sig-
niﬁcant, it was not expected to result in such a noteworthy
difference in the overall survival between the treatment
group and the control. An alternative explanation was
sought, that could account for the observed differences in
the overall survival. Hence, we investigated the metastatic
spread of the VX-2 tumors to the lungs [21].
Fig. 6 Exemplary photos of
surface lung metastases in
TTFields treated (a) versus
sham control rabbits (b).
Treatment was initiated on day
12 from implantation of the
kidney tumor. The average total
number (±SD) of surface
metastases (c) and the average
number of large metastases
(±SD) (d) in control versus
treated rabbits
Table 1 Lymphocyte inﬁltration in lung tumors as revealed by
immuno-histochemical staining
Treatment CD4 CD8 CD45 CD19
Control 2.0 ± 0.8 0.8 ± 0.5 2.0 ± 0.8 0
TTFields 3.4 ± 0.9 1.6 ± 0.5 3.6 ± 0.5 0
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The TTFields intensity in the lungs was about 20% of the
ﬁelds’ intensity in the kidney (data not shown). Such a
0.5 V/cm ﬁeld intensity measured in the rabbit’ lungs is
below the threshold required for cancerous cell growth
inhibition [19]. Since the TTFields application could not
account for the decrease in the number of metastases, we
searched for an alternative explanation for the results.
One such explanation relates to the inhibition of growth
of the primary renal tumor. It is possible that by lowering
the tumor load in the kidney, the metastatic potential of the
tumor would decrease proportionately. Another possibility
is based on the reported ﬁnding that there is an increase in
metastatic spread of VX-2 tumors from the kidney between
days 12 and 15 from implantation [21]. Here we report that
treating the primary tumor with TTFields after day 15 from
implantation resulted in a smaller difference between
treated and control rabbit in the number of lung metastases.
Therefore, it is possible that the inhibition of metastatic
spread is due to an inhibitory effect on the capability of the
tumor cells to migrate into the circulation of the primary
tumor. Such migration is dependant on the proper forma-
tion of a microtubule based processes in the migrating cells
[22]. Although we did not test this directly, the known
inhibition of microtubule polymerization by TTFields
during mitosis may have a similar effect on cancer cell
migration and endothelial penetration. Future experiments
are warranted to test this point directly.
An additional explanation for our ﬁndings is the
enhancement of a systemic immune response to the tumor
cells. This option is supported by the results of the immu-
nostaining assay performed on treated and sham control
lungs. It is becoming widely accepted that immune response
can inhibit the proliferation of cancerous cell or even
eliminate them (reviewed by Dunn et al. [23]), and thus
account for the reduction in the number of metastases.
Naturally, the following question would be: How could
TTFields activate the immune response in an organ distant
from the location where the ﬁelds are applied? Zitvogel
et al. [14] reviewed several mechanisms through which
conventional treatments could modulate the interaction
between the tumor and the immune system: reduction of the
tumor mass as a result of chemotherapy, surgery or radia-
tion could reduce the tumor immunosuppressive properties;
tumor cell destruction induced by chemotherapy or radia-
tion could expose hidden tumor antigens; stimulation of the
immune system through activation of immune effectors and
regulatory mechanisms or by inducing lymphopenia fol-
lowed by proliferation of immune effectors. Taken together,
a self generated vaccination against cancer speciﬁc antigens
may develop—leading to metastasis destruction by the
immune system [14]. In addition, we found that the cells
inﬁltrating the lung metastases in the TTFields group were
CD4, CD8 and CD45 positive. This milieu of immune
markers indicates a T-cell mediated immune response;
however, it is not yet sufﬁcient to prove a tumor-antigen
speciﬁc immune reaction. Interestingly, CD45 activation
can induce the production of TNFa [24] which in turn
activates a family of cell-surface receptors that can mediate
cell death.
Assuming that the activation of the immune response in
the rabbits’ lungs was mediated by the TTFields treatment,
a question arises regarding the TTFields effect on the
immune system in the mice. The observation that the
metastases renewed their growth in the lungs, once the
TTFields application to the mice was terminated, does not
support immune response activation in the treated group. It
Fig. 7 Discrete intra-tumoral inﬁltration of CD45 positive T cells in control tumours (a) and abundant intra-tumoral CD45 positive T cells in
TTFields treated tumours (b). Scale bar 100 lm
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the mice lungs was due to a direct inhibitory effect of the
TTFields on the cancerous cells. Unlike the rabbits in
which there was a substantial difference between the ﬁelds’
intensities in the lungs and the kidneys, in the mice lungs
the TTFields intensity was sufﬁciently large to induce
inhibition of the metastasis. Why wasn’t the immune sys-
tem activated in the mice? The shorter treatment duration
(1 week in mice compared to 5 weeks in rabbits) might not
sufﬁce for the induction of the immune response in mice.
Differences between the cancerous cell lines used (VX-2
carcinoma in rabbits and B16F10 melanoma in mice) as
well as differences between the animals’ immune system
could also account for these results. In addition, the tumors
subjected to TTFields application in the rabbits were
established large tumors which provided a larger target for
the immune system and possibly presenting more tumor
speciﬁc antigens after the TTFields treatment.
In conclusion, we have shown that TTFields have the
potential to inhibit the migration of metastases from a
primary tumor, can inhibit the growth of metastases in the
lungs once they have been seeded in the target organ, by
the presence of the ﬁelds in the lungs themselves, and
ﬁnally, TTFields may activate an anti-tumor antigen sys-
temic immune response following treatment of a primary
tumor. Therefore, TTFields may not only be clinically
useful in treatment of locally advanced tumors, but in
prevention and treatment of metastatic disease as well.
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